CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:
Net income (loss)	$ (142,450)	$ 1,798,073
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock compensation expense	821,586	497,055
Foreign exchange loss	1,621	0
Contingent consideration adjustment	(18,395)	0
Depreciation and amortization	1,085,691	990,743
Noncash interest expense	29,934	29,934
Provision for doubtful accounts and sales returns	52,358	9,976
Inventory reserves	59,353	0
Deferred income taxes	(218,778)	(500,704)
(Increase) decrease in:
Accounts receivable, net	(1,858,509)	537,891
Inventories	37,312	22,459
Costs in excess of billings	408,240	135,157
Prepaid expenses and other current assets	(355,323)	(67,338)
Increase (decrease) in:
Accounts payable	1,072,689	151,238
Accrued expenses and other liabilities	(344,271)	(384,455)
Net cash provided by operating activities	631,058	3,220,029
Cash flows from investing activities:
Purchases of property, plant and equipment	(764,028)	(1,294,343)
Acquisition of Biomedical Technologies	0	(300,000)
Net cash used in investing activities	(764,028)	(1,594,343)
Cash flows from financing activities:
Proceeds from issuance of common stock	50,604	123,489
Repayment of long-term debt	(1,432,581)	(1,395,105)
Preferred stock dividends paid	0	(79,770)
Net cash used in financing activities	(1,381,977)	(1,351,386)
Effect of exchange rates on cash and cash equivalents	21,419	258,131
Net change in cash and cash equivalents	(1,493,528)	532,431
Cash and cash equivalents, beginning	4,479,840	4,111,966
Cash and cash equivalents, ending	$ 2,986,312	$ 4,644,397